Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.94 USD | -1.40% | +9.37% | +12.80% |
06-18 | Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Ahead of Speeches by Fed Officials | MT |
06-14 | Oppenheimer Adjusts UroGen Pharma Price Target to $40 From $32, Maintains Outperform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.80% | 621M | |
+16.54% | 122B | |
+20.11% | 115B | |
+21.22% | 26.64B | |
-23.50% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.65% | 15.49B | |
+61.93% | 14.83B | |
+2.69% | 13.67B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Transcript : UroGen Pharma Ltd., Q3 2022 Earnings Call, Nov 10, 2022